华润三九医药股份有限公司 关于回购注销部分限制性股票通知债权人的公告

Core Viewpoint - The company, China Resources Sanjiu Medical & Pharmaceutical Co., Ltd., has announced the repurchase and cancellation of a portion of restricted stock due to the termination of employment of several incentive plan participants [2][3]. Group 1: Stock Repurchase and Cancellation - The company held its fifth extraordinary general meeting on September 1, 2025, where it approved the repurchase and cancellation of 36,505 restricted shares, which accounts for approximately 0.002% of the company's total share capital prior to the repurchase [2][3]. - Following the repurchase, the total share capital will decrease from 1,664,254,363 shares to 1,664,217,858 shares [3]. Group 2: Debt Creditor Notification - The company has informed creditors that they have 45 days from the announcement date to claim debts or request guarantees due to the reduction in total share capital [4][5]. - Creditors must provide valid documentation to substantiate their claims, including contracts and agreements [4][5]. Group 3: Shareholder Meeting Details - The extraordinary general meeting was conducted using both on-site and online voting methods, with specific time slots allocated for voting [13]. - The meeting's resolutions included the approval of the repurchase of restricted stock and the reappointment of the auditing firm for the 2025 fiscal year, both of which received overwhelming support from shareholders [17][19].